Dante Labs appoints Illumina acclaimed COO Bob Ragusa as Board Member to support the execution of its global integrated preci...
July 19 2021 - 7:07AM
Dante Labs, a global leader in genomics and precision medicine,
announced today the appointment of Bob Ragusa as a board member.
Bob is the Chief Operations Officer of Illumina Inc. (NASDAQ:
ILMN), the world leader in sequencing platforms.
Mr. Ragusa stated, “I am very excited to work with Dante to help
bridge from improved genomic tools and scientific discovery to
positive impact for patients.”
Dante Labs CEO Andrea Riposati stated, “As Illumina customers,
we have been amazed by Illumina’s global customer support and
operational excellence. Bob is responsible for leading these
achievements and for supporting clinical and research labs
globally. Bob is a life science rockstar and will help us deploy
our global commercial and clinical offering for multi-omics and
integrated precision medicine. The entire team at Dante Labs is
excited to have his leadership and guidance to support our
ambitious growth plan.”
Intersection of Data and Clinical Outcomes
Massive adoption of whole genome sequencing requires changing
the paradigm of lab operations and data analysis. Dante Labs has
learned the hard way and built the skills to enable massive
adoption of whole genome sequencing on a global scale, by working
with patients, doctors and companies in 97 countries and generating
thousands of clinical and consumer reports every day.
The appointment of Bob Ragusa as a board member has a great
strategic fit with the company’s global scaling and growth
aspirations. Dante Labs leverages local labs to develop local
domain expertise while connecting all local operations in its
global network to have superior collective wisdom in every
market.
- Dante Labs integration of software
and data with the actual biology in the labs generates unique
insights and enables a continuous feedback loop.
- Dante Labs acquisition of CCG has
created a global excellence in precision oncology with the
potential of impacting patients worldwide, with a total addressable
market of $75 billion.
- Dante Labs built a stellar team for
population genomics and precision medicine.
- Over 40 countries are actively
involved in population genomics programs with many more that can
benefit from genome-based preventative medicine for their
citizens.
- Dante Labs serves its customers
across 97 countries from clinical laboratories and sequencing
centres in the United Kingdom and Italy, with at least two more
planned in 2021 to expand its global footprint.
About Dante Labs
Dante Labs is a global genomic data company building and
commercialising a new class of transformative health and longevity
applications based on whole genome sequencing and AI. Our assets
include one of the largest private genome databases with research
consent, a proprietary software platform designed to unleash the
power of genomic data at scale and proprietary processes which
enable an industrial approach to genomic sequencing.
Headquartered in Cambridge, United Kingdom, with a research
laboratory in Wolverhampton, Dante Labs supported the UK
Government’s urgent requirement to scale-up a high-capacity, highly
automated testing solution for Covid-19, including infected
patients as well as those with antibodies. Dante Labs was able to
deliver by leveraging existing technology that had been developed
for whole genome sequencing.
Giorgio Lodi, media@dantelabs.com. +39 0862 191 0671
www.dantelabs.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024